Brief: Scienture Provides Commercial Update On Arbli™, The First FDA-Approved Ready-To-Use Oral Suspension Of Losartan Potassium

Scienture Holdings

03/02/2026 13:35

Feb 3 (Reuters) - Scienture Holdings Inc SCNX.O:

SCIENTURE PROVIDES COMMERCIAL UPDATE ON ARBLI™, THE FIRST FDA-APPROVED READY-TO-USE ORAL SUSPENSION OF LOSARTAN POTASSIUM

Source text: ID:nGNX5bjMV

Further company coverage: SCNX.O

 ((Reuters.Briefs@thomsonreuters.com;))